An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.

Inclusion Criteria:

• Chinese.
• Diagnosis of bacterial conjunctivitis based on clinical observation.
• Understand and sign the approved informed consent. Legally authorized representative can provide informed consent for patients less than 18 years old and/or incapable of understanding the informed consent.
• Willing to complete all required study procedures and visits.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Women who are pregnant, lactating, or planning a pregnancy.
• Only 1 sighted eye or vision not correctable to 0.6 logMAR or better in either eye.
• Planned contact lens wear during the course of the study.
• Signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to Screening (Day 1).
• Suspected fungal, viral, or Acanthamoeba infection.
• Any systemic or ocular disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study.
• History of recent surgery.
• Presence of concomitant systemic viral infection.
• Other protocol-defined exclusion criteria may apply.